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Abstract 
ERG, an oncoprotein in prostate carcinoma and Ewing’s sarcoma is associated with poor 
prognosis in patients with acute myeloid leukemia and T lymphoblastic leukemia. However little 
is known about ERG in lymphoma. Here we studied ERG in diffuse large B-cell lymphoma 
(DLBCL) by immunohistochemistry, fluorescence in situ hybridization (FISH), genome-wide 
miRNA expression profiling, real-time reverse transcriptase polymerase chain reaction (RT-
PCR) and whole exome sequencing (WES).  Approximately 30% of de novo DLBCLs (37/118) 
expressed ERG (ERG+). ERG expression showed no significant correlation with DLBCL cell-
of-origin classification, patient’s age, gender, nodal or extranodal disease status, tumor 
expression of p53 or p63. There was no ERG rearrangement in ten randomly selected ERG+ 
DLBCLs by FISH. Forty-three miRNAs showed significant differential expression between 
ERG+ and ERG-negative DLBCLs. Downregulation of miR-4638-5p was confirmed by real-
time RT-PCR. WES not only confirmed known gene mutations in DLBCLs but also revealed 
multiple novel gene mutations in POLA1, E2F1, PSMD8, AXIN1, GAB2 and GNB2L1, which 
occur more frequently in ERG+ DLBCLs. In conclusion, our studies demonstrated aberrant ERG 
expression in a subset of DLBCL, which is associated with downregulation of miR-4638-5p. In 
comparison with ERG-negative DLBCL, ERG+ DLBCL more likely harbors mutations in genes 
important in cell cycle control, B-cell receptor-mediated signaling and degradation of beta-
catenin. Further clinicopathological correlation and functional studies of ERG-related miRNAs 
and pathways may provide new insight into the pathogenesis of DLBCL and reveal novel targets 
for better management of patients with DLBCL. 
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Background  
ERG (avian v-ets erythroblastosis virus E26 oncogene homolog), a member of ETS family 
transcription factor is physiologically expressed in endothelial cells and hematopoietic precursor 
cells. [1-3] In hematopoietic system, ERG expression is essential for normal hematopoiesis 
including megakaryopoiesis. [4]Aberrant ERG expression via ERG-involved translocation has 
been well documented in prostate carcinoma, Ewing’s sarcoma and rare cases of acute myeloid 
leukemia (AML). [5-8]Aberrant ERG expression (ERG+) is associated with poor prognosis in a 
subgroup of cytogenetically normal AML and T lymphoblastic leukemia (T-ALL) while deletion 
of ERG locus is associated with a subset of B lymphoblastic leukemia (B-ALL) with good 
prognosis. [9-13] Targeted therapy against ERG either directly or indirectly to ERG-involved 
pathway has shown promising results in prostate carcinoma. [14-16]However little is known 
about ERG expression in mature hematopoietic cell neoplasm. 
Diffuse large B-cell lymphoma (DLBCL) is one of the most common lymphomas with close to 
50% of treatment failure in patients receiving current standard chemotherapy. [17]Novel 
treatment modality particularly targeted therapy based on specific pathways involved in DLBCL 
are currently being actively pursued. Following our initial observation of ERG expression in an 
index DLBCL case, we decided to study systematically ERG expression in DLBCL. 
miRNAs are small non-coding RNAs that regulate gene expression at the post-transcription 
level. They are involved in many important biological processes such as development, 
differentiation, apoptosis and proliferation. Systematic studies such as miRNA library profiling 
and miRNA sequencing have identified many miRNAs, which are involved in tumor initiation, 
progression and are used as markers for cancer diagnosis, prognosis stratification and targeted 
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therapy. [18]Though there are several miRNA studies in DLBCLs, there is no reported miRNA 
study about ERG+ DLBCLs.[19-23]   
In the current study, we first studied ERG expression in normal hematopoietic tissue and then in 
DLBCL. miRNA profiling was then performed in 16 ERG+ and 23 ERG- DLBCLs. 
Furthermore, whole exome sequencing data from 5 ERG+ and 13 ERG- DLBCLs were 
compared. We established ERG aberrant expression in a subset of DLBCLs, which is associated 
with differential expression of a group of miRNAs. The genetic mutation and its associated 
pathways that may are more commonly seen in ERG+ DLBCLs were identified.  
Materials and methods    
Clinical cases and immunohistochemistry 
Tissue microarrays (TMAs) were constructed from our archival cases of de novo DLBCL 
diagnosed during 2000-2014 following approval by the Institutional Review Board of our 
Institute. Clinical information was collected from the medical records.  
TMAs for DLBCLs were stained with antibodies against CD20, BCL-2, CD10, BCL-6, and 
MUM-1. Prediluted, ready-to-use antibodies (CD20, GA604; CD10, GA648; BCL2, IR614; 
BCL6, GA625; MUM-1, GA644; ERG, IR659; CD31, GA610 from Dako, Santa Clara, CA; 
LMO2, 370R and HGAL, 375M from Cell Marque, St. Louis, MO) were used with a Dako 
Autostainer Plus instrument following the manufacturer’s protocols (www.dako.com). DLBCL 
cases were classified as either germinal center B-cell-like (GCB) or non-germinal center B-cell-
like (non-GCB) subgroup based on Han’s algorithm. [24]To confirm the ERG expression 
identified in TMAs, tissue sections from 10 randomly selected ERG+ DLBCLs based on the 
TMA study were directly stained for ERG. 
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A DLBCL is considered ERG+ when at least one of the two duplicate cores (1.0 mm in 
diameter) in the TMAs were positive for CD20 and showed moderate to strong nuclear 
expression of ERG in over 50% of tumor cells. The background weak scattered staining of ERG 
in reactive germinal centers from tonsils present in each TMA was defined as negative. 
Accordingly, a total of 118 DLBCL individual cases were successfully determined for its ERG 
expression status. In addition, tissue sections from another eight DLBCL cases were directly 
stained for ERG. A total of126 DLBCL cases were included in Kaplain-Meier survival analysis. 
Among the 118 DLBCL in TMAs, 94 of them were successfully stained for CD10, BCL-6 and 
MUM-1 and subsequently classified as either GCB or non-GCB DLBCLs. These 94 cases were 
included in the clinicopathologic correlation study.        
ERG-rearrangement study by fluorescence in situ hybridization (FISH) 
FISH study was performed as described before. [25]Briefly, 4-micron tumor tissue sections from 
10 randomly selected ERG+ DLBCLs were mounted on positively- charged glass slides. An 
accompanying H & E slide was reviewed to determine tumor location. Slides were baked at 65oC 
+/- 5oC for 1 hour, de-paraffinized in xylene at room temperature and washed in 100% ethanol 
and air-dried. Pretreatment included exposure to 0.2 N HCl, followed by 1M sodium thiocyanate 
and pepsin at 37oC to digest proteins in the tissue sample. Following pepsin treatment, slides 
were viewed with phase microscopy to ensure adequate digestion of the tumor tissue. 
Denaturation, ethanol dehydration, and hybridization with a probe cocktail including BAC 
clones RP11-476D17-gold (3’ ERG) and RP11-95121-green (5’ ERG) (Empire Genomics, 
Buffalo, NY, USA) diluted 1:25 in tDenHyb2 (Insitus, Albuquerque, NM, USA). Cells were 
counterstained with DAPI and observed under a Leica DMRXA2 fluorescence microscope. Two 
hundred cells were analyzed by two readers (100 cells apiece) for each of the three probes. 
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Scoring criteria included the selection of single nuclei with representation of at least one signal 
for each color/probe/ nucleus. Tissue sections from prostate carcinoma with known ERG 
rearrangement were used as the positive control. 
miRNA microarray analysis 
Total RNA was extracted from formalin fixed paraffin embedded (FFPE) tissue using 
RecoverALLTM Total Nucleic Acid Isolation kit (Invitrogen, Carlsbad, California) following the 
manufacturer’s instructions. RNA quality and quantity were measured using NanoDrop 
spectrophotometer. 1.0 µg total RNA samples were labeled using T4 Rnl2tr-K227Q kit (New 
England BioLabs, Ipswich, MA) according to the manufacturer’s instructions. Human miRNA 
Array (miRHuman_21, LC Sciences, Houston, Texas), which contained the entire 1881 miRNAs 
annotated in Sanger miRBase Release 21 were used. Hybridization was performed overnight on 
a µParaflo microfluidic chip using a micro-circulation pump (Atactic Technologies, Houston, 
TX). [26]Fluorescence images were collected using a laser scanner (GenePix 4000B, Molecular 
Device, San Jose, CA) and digitized using Array-Pro image analysis software (Media 
Cybernetics, Rockville, MD).  Data were analyzed by first subtracting the background and then 
normalizing the signals using a LOWESS filter (Locally-weighted Regression).[27] 
Quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay 
Total RNA including miRNAs were extracted from FFPE tissue samples using miRNeasy FFPE 
kit (QIAGEN, Hilden, Germany). The quantity of total RNA was determined by Qubit RNA HS 
Assay kit (Thermo Fisher Scientific, Waltham, MA). Reverse transcription was performed using 
miScript II RT kit (QIAGEN) with HiFlex buffer. Real-time qPCR was performed using 
miScript SYBR Green kit (QIAGEN) according to the manufacturer’s protocol on a QuantStudio 
5 Real-time PCR system (Thermo Fisher Scientific). Universal forward primer included in the kit 
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and primers included in the miScript primer assay (QIAGEN) were used to quantify the 
expression of miRNAs. Two housekeeping small RNAs, RNU6B and SNORD68, were also 
included as internal controls. Relative expression (RE) of miRNAs was measured as RE = 2-ΔΔCt. 
Whole exome sequencing, variant calling and pathway prediction 
The whole exome sequencing (WES) of 5 ERG+ and 13 ERG- DLBCLs was performed at the 
Technology Center for Genomics & Bioinformatics at University of California at Los Angeles.  
Whole-exome DNA was captured from total genomic DNA using the SeqCap EZ System from 
NimbleGen according to the manufacturer’s instructions. Briefly, genomic DNA extracted from 
FFPE tumor tissue was sheared, size selected to roughly 200-250 base pairs, and the ends were 
repaired and ligated to specific adapters and multiplexing indexes. Fragments were then incubated 
with SeqCap biotinylated DNA baits followed by the LM-PCR, and the RNA-DNA hybrids were 
purified using streptavidin-coated magnetic beads. The RNA baits were then digested to release 
the targeted DNA fragments, followed by a brief amplification of 15 or less PCR cycles. The 
libraries were then sequenced on the HiSeq 3000 platform from Illumina, using 150-bp pair-ended 
reads. The sequence data were aligned to the GRCh37 human reference genome using BWA 
v0.7.7-r411. PCR duplicates were marked using MarkDuplicates program in Picard-tools-1.115 
tool set.  Samtools was used to call the SNVs (single nucleotide variants) and small INDELs 
(insertions and deletions). Varscan2 was used to call the somatic SNVs. All variants were 
annotated using the Annovar program. The top 203 genes showing greater than 0.5 difference in 
the frequency of the nonsynonymous SNV in genes between ERG+ and ERG- DLBCLs were used 
for pathway prediction. StrandNGS software and the Wikipathways database were used for 
pathway analysis. 
Statistical analysis 
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SPSS Statistics24 software (IBM Corporations, New York, NY) was used to generate Kaplan-
Meier survival curve. Pearson’s chi-squared test was used for comparison with a p value of less 
than 0.05 being considered as significant.    
Results 
ERG expression in normal hematopoietic tissue 
To characterize ERG expression in normal hematopoietic tissue, two reactive lymph nodes, two 
tonsils and two spleens were stained for ERG. Reactive follicles with well-defined germinal 
centers from a reactive lymph node were shown in Fig.1A. As shown in Fig.1B and 1C, ERG 
was expressed as a nuclear protein, predominantly in cells outside of the germinal centers. The 
weak nuclear and cytoplasmic stain noted in germinal center cells may represent non-specific 
background staining. The ERG expression within reactive lymphoid tissues is similar to that of 
BCL-2 (Fig.1D). There is similar ERG staining pattern in reactive tonsils and spleens (data not 
shown).  
ERG expression in a subset of diffuse large B-cell lymphoma 
As we initially made an incidental observation of high ERG expression in a bladder DLBCL 
(Fig. 2A-D), we decided to study ERG expression by staining TMAs containing a series of de 
novo DLBCLs (Fig. 2E-F). ERG is expressed in approximately one-third of DLBCLs. Tissue 
sections from ten randomly selected ERG+ DLBCLs were also directly stained for ERG, which 
showed complete correlation with ERG expression observed in TMAs (result not shown). 
To investigate if ERG expression may be due to ERG rearrangement as seen in approximately 
50% of prostate carcinomas, FISH using a break-apart ERG probe was performed on these 10 
ERG+ DLBCL cases. Prostate carcinoma case with confirmed ERG translocation was used as 
the positive control in the FISH study. None of DLBCLs tested showed ERG rearrangement 
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(data not shown), indicating that other mechanism may contribute to ERG overexpression in 
ERG+ DLBCLs. 
To correlate ERG expression with the clinicopathological features of DLBCL, TMAs were 
stained for CD20, CD10, BCL-6, MUM-1, p53, p63 as well as ERG.  A total of 94 de novo 
DLBCLs were successfully stained and classified as GCB or non-GCB subgroups based on 
Hans’ algorithm. [24]As shown in Table 1, ERG moderate to strong expression was seen in both 
GCB and non-GCB DLBCL cases with no significant difference (p=0.603) and showed no 
significant correction with patient’s age (p=0.688), gender (p=0.826), nodal or extranodal disease 
status (p=0.903), tumor expression of p53 (p=0.672) or p63 (p=0.640). A total of 126 patients 
with ERG determined status were included in the overall survival analysis. ERG+ DLBCL 
showed no difference in overall survival compared with ERG- DLBCL (p=0.940). However, in 
patients with treatment of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone 
(R-CHOP, n=54), ERG+ DLBCL patients started to show a trend toward inferior overall survival 
(p=0.192) though the patient cohort became much smaller (Fig. 3). 
miRNA signatures of ERG+ vs ERG- DLBCLs and downregulation of miR-4638-5p in 
ERG+ DLBCL  
To study the miRNAs expression in ERG+ DLBCLs, we performed whole-genome miRNA 
library profiling on 16 ERG+ and 23 ERG- DLBCLs using Human miRNA Array 
(miRHuman_21, LC Sciences, Houston, Texas), which contained the entire 1881 miRNAs 
annotated in Sanger miRBase Release 21. To investigate if the miRNA array screening was 
working adequately, we compared first the miRNA expression between GCB and non-GCB 
DLBCLs. In our current study, the following 10 miRNAs (miR-221-3p, miR-155-5p, miR-4267, 
miR-148a-3p, miR-151a-5p, miR-222-3p, miR-151-b, miR-615-5p, miR-138-5p, and miR-3197) 
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showed most significant difference in the expression level between GCB and non-GCB 
DLBCLs.  Six of them (miR-221-3p, miR-155-5p, miR-151a-5p, miR-222-3p, miR-151-b, and 
miR-138-5p) have been reported in the previous studies, which confirmed the validity of our 
current assay. [28] There is no available information about the remaining four miRNAs in 
DLBCLs. Next we compared the ERG+ versus ERG- DLBCLs. We identified forty-three 
miRNAs, which showed significantly different expression levels (p<0.05) (Fig. 4A). Twenty-six 
miRNAs were downregulated and 17 upregulated in ERG+ DLBCLs compared with ERG-
DLBCLs. Four miRNAs miR-4638-5p, miR-1273c, miR-6780a-5p and miR-203a-3p showed 
more than 2-fold reduction in ERG+ DLBCL and had relatively high signals in the array study. 
miR-4638-5p was the only one with mean signal > 500 in both ERG+ and ERG- DLBCLs, 
which was the recommended cutoff by the manufacturer.  To confirm the above findings, we 
performed quantitative real-time RT-PCR analysis for the above four miRNAs in the same 39 
samples used for miRNA array analysis. Expression of miR-4638-5p was significantly lower and 
there was a trend of downregulation of miR-6780a-5p in ERG+ DLBCLs. There was essentially 
no difference for the expression of miR-1273c and miR-203a-3p between ERG+ vs ERG- 
DLBCLs (Fig. 4B).  
Identification of genes with genomic alterations in ERG+ DLBCL 
To gain an insight on the potential pathways associated with ERG+ DLBCLs, we analyzed WES 
data obtained from 5 ERG+ and 13 ERG- DLBCLs. To validate and compare our WES 
sequencing and analysis with previously published ones in DLBCLs, we analyzed the genomic 
alterations of a group of 15 genes known to be important in DLBCLs. As shown in Table 2, our 
study showed significant overlap with the previous studies. [29, 30]As our study did not include 
any normal matched DNAs for normal individual variant control, the much higher alteration 
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frequency seen in genes TNFRSF14, TP53, PCLO may reflect the normal individual variation 
that was not completely filtered during our analysis. It may also reflect random sample bias 
introduced by our relative small sample size. To mitigate this effect and identify genes that show 
difference in mutation frequencies between ERG+ and ERG- DLBCLs, we focused on 203 
genes, which showed more than 0.5 in genomic alteration frequency between ERG+ and ERG- 
DLBCLs (Table S1). To identify the genomic pathways, which may be significantly impacted by 
alterations in these 203 genes, we calculated the p-value, which reflects how significant the 
pathway change is based on a gene’s variants by combining what mutation a gene has and how 
significant the mutated gene is in the pathway. The predicted pathways affected by these 203 
genes in ERG+ and ERG- DLBCLs were summarized in Table S2. The detailed information 
about the underlying genes was summarized in Table S3 for ERG+ DLBCLs and Table S4 for 
ERG- DLBCLs. In addition, we reported for the first time mutations in six genes POLA1, E2F1, 
PSMD8, AXIN1, GAB2 and GNB2L1, which occur more frequently in ERG+ DLBCLs. Their 
mutation frequencies vary from 0.6 to 0.8 in ERG+ DLBCLs and 0 to 0.23 in ERG- DLBCLs. 
The types of mutations include silent, missense, nonsense and frameshift (Table S5). Five of 13 
pathways were significantly affected by ERG expression in DLBCLs and their involved genes 
were summarized in Table 3. The Table S6 summarized the detailed findings for the involved 
genes.   
Discussion 
ERG is a well-established oncogene in prostate carcinoma. ERG overexpression in a subset of 
AML and T-ALL impacts negatively towards patient’s prognosis, possibly by inducing 
chemoresistance in leukemia cells.[31]Recently ERG dysregulation at both transcriptional and 
translational levels is documented in a subset of B lymphoblastic leukemia as well. [12]ERG is 
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emerging as an important prognostic marker as well as a novel therapeutic target. However, there 
has been no systematic study about ERG in lymphomas. Here we reported ERG expression in a 
subset of DLBCL. 
Our study showed moderate to strong ERG expression in approximately 30% of de novo 
DLBCLs including both GCB and non-GCB groups without significant difference. The ERG 
overexpression in ERG+ DLBCLs is unlikely due to ERG gene rearrangement as 10 randomly 
selected ERG+ DLBCL cases were all negative for ERG rearrangement by FISH study. Though 
our FISH study for ERG rearrangement is small, it nevertheless suggests that other mechanisms 
may be involved as seen in most ERG+ AML and T-ALL. [12, 32-34]Though ERG expression 
appears not to correlate with any clinicopathological features we have studied, it does point to a 
trend that patients with ERG+ DLBCL might behave more poorly compared to those with ERG-
DLBCLs when receiving current standard chemotherapy (rituximab, cyclophosphamide, 
doxorubicin, vincristine and prednisone; R-CHOP), especially in the first three years after the 
diagnosis. However, the cohort is too small and we did not have the follow-up on many of our 
patients as they were treated in the outside facilities after the diagnosis. Additional studies with 
much larger cohort of patients are needed to investigate if ERG expression may confer a worse 
prognosis. 
As miRNA’s role in the regulation of gene expression at the post-transcription level is well 
established, we decided to study miRNAs expression through genome-wide miRNA profiling. 
Of the 43 miRNAs showing differential expression in ERG+ vs ERG-DLBCLs, only miR339-3p 
and miR-320b have been previously reported to be involved in DLBCL. [19, 35] miR-106b-5p, 
mir-5787, miR-192-5p, miR106-5p, miR-378-3p have been however implicated in cellular 
growth, tumorigenesis, tumor progression, metastasis and sensitivity to chemotherapy in other 
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types of tumor. [36-43]Interestingly none of the 43 miRNAs were predicted to directly regulate 
ERG expression based on miRDB curation (www.mirdb.org), suggesting either their indirect role 
in the regulation of ERG overexpression or their expression is impacted by aberrant ERG 
expression in DLBCLs.  
While miRNA array expression profiling is a very sensitive and powerful technology in 
identifying the differentially expressed miRNAs among different study groups, it is important to 
validate these findings by another methodology, such as quantitative real-time RT-PCR.  Among 
the four miRNAs selected for RT-PCR study, the significant downregulation of miR-4638-5p in 
ERG+ DLBCLs was confirmed, while a trend of downregulation of miR-6780a-5p in ERG+ 
DLBCLs was observed by real-time RT-PCR. There were essentially no differences for the 
expressions of miR-1273c and miR-203a-3p between ERG+ vs ERG- DLBCLs. While the result 
was not entirely surprising as miR-4638-5p was the only miRNA with mean signal > 500 in both 
ERG+ and ERG- DLBCLs in miRNA array study, which was the recommended cutoff by the 
manufacturer, it emphasizes the importance of cross validation by different methodologies in 
miRNA study.  
In prostate carcinoma, downregulation of miR-4638-5p is associated with castration resistance 
though its direct repression of protein kinase D-interacting substrate of 220 KDa (kidins200) and 
PI3K/AKT pathway activity. [44]In resting and stimulated B cells, kidins200 interacts with B-
cell antigen receptor (BCR) and positively regulates pre –BCR and BCR functioning. [45]In T 
cells kidins200 associates with B-Raf and the T-cell antigen receptor to promote sustained Erk 
signaling. [46]Whether similar mechanism may be involved in ERG+ DLBCL warrants further 
studies.        
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In summary, we report for the first time that ERG is expressed in up to one-third of DLBCL, 
which raises the caution in its use as a diagnostic marker for cutaneous leukemia involvement. 
[47] Through genome-wide miRNA study, we identified and confirmed that miR-4638-5p was
significantly associated with aberrant ERG expression in DLBCLs. WES and subsequent 
pathway analysis reveal several cellular pathways significantly associated with genomic 
alterations preferentially seen in ERG+ DLBCLs. Further studies will not only decide whether 
ERG may be used as a novel prognostic and/or therapeutic marker in DLBCL, but also help us 
understand the general oncogenic role of ERG in tumorigenesis. 
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Legends of figures: 
Figure 1. ERG expression in reactive lymph node. A, hemotoxylin-eosin stained lymph node 
section showing reactive follicles with well-defined germinal centers, 100X. B to D- 
immunohistochemistry. B, C-ERG expression, B-100X, C-400X. D, BCL-2 expression, 200X. 
Figure 2. ERG expression in a subset of diffuse large B-cell lymphoma. A-D tissue section (x 
100): A- H&E, B-CD20, C-BCL-6, D-ERG; E-F TMA section (x 40): E-CD20, F-ERG. 
Figure 3. Patients with ERG+ DLBCL associated with a tendency for inferior survival when 
treated with R-CHOP. Kaplain-Meier survival analysis.  
Figure 4. A Differential expression of 43 miRNAs in ERG+ vs ERG- DLBCLs identified by 
miRNA library profiling; B Downregulation of miR-4638-5p in ERG+ vs ERG- DLBCLs 
measured by real-time RT-PCR.  
